Cardiac magnetic resonance (CMR) it is a technique without radiation, which is considered the gold-standard for the evaluation of cardiac anatomy, function and even tissue composition. The RESILIENCE trial will use CMR as the main outcome measure methodology, and patients enrolled in the trial will undergo 3 scans across the duration of the study.
Multinational, prospective, proof of concept phase II, double-blinded, sham-controlled, randomized clinical trial (RCT) to evaluate the efficacy and safety of Remote Ischaemic Conditioning (RIC) in Lymphoma patients receiving anthracyclines. Patients scheduled to undergo ≥5 chemotherapy cycles will be eligible.
We are glad to announce that in October 13th new centers have joined the RESILIENCE project, welcome to our team to Hospital Clínico Universitario de Valladolid! This is great news as during the summer 2022 three new sites have also been opened: • Hospital Universitario de Salamanca, July 22nd. •
We were at the European Society of Cardiology Barcelona 22 congress at the end of August, where Borja Ibáñez, Director of the Clinical Research Department at Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC) and Coordinator of the RESILIENCE project discussed the role of cardiologist on the anthracycline-induced cardiotoxicity along
Our RESILIENCE team has prepared this video in which we explain how the therapy is randomized for the RESILIENCE clinical trial. For this procedure, we will use the electronic case report form (e-CRF), a software that will assign one of the corresponding therapies randomly. The research team will access to
Interview with Alberto López-García – Fundación Jiménez Díaz University Hospital (IIS-FJD) Alberto is a young researcher leading an important part of the project. Alberto represents the young community of the project. One of the goals of RESILIENCE is to identify the European leaders of the future. Could you tell us
La Comisión Europea, a través del programa H2020 “Salud, Cambio Demográfico y Bienestar”, ha designado al Centro Nacional de Investigaciones Cardiovasculares (CNIC) como coordinador de RESILIENCE (REmote iSchemic condItioning in Lymphoma PatIents REceiving ANthraCyclinEs), un ambicioso proyecto especialmente diseñado para desarrollar una nueva intervención médica destinada a reducir la prevalencia
Cancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse cardiovascular effects. Every year, more than 3 million Europeans receive aCancer patients are a vulnerable population prone to develop cardiovascular complications. Among other factors, some anticancer therapies can induce adverse
